This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Infants and young children are at greatest risk for mortality from epidemic flu and children are disproportionately impacted by the H5N1 strains of influenza which are considered possible sources of the next inluenza pandemic. This study will look at the pharmacokinetics and safety of oseltamivir in children younger than 2 years to determine the appropriate dose for this age group. There are currently no other antivirals available to young children affected with influenza.
Showing the most recent 10 out of 230 publications